U.S. market Closed. Opens in 4 hours 53 minutes

PMVP | PMV Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.5400 - 1.5850
52 Week Range 1.4000 - 3.47
Beta 1.65
Implied Volatility 559.48%
IV Rank 100.00%
Day's Volume 108,185
Average Volume 201,273
Shares Outstanding 51,747,100
Market Cap 81,242,947
Sector Healthcare
Industry Biotechnology
IPO Date 2020-09-25
Valuation
Profitability
Growth
Health
P/E Ratio -1.57
Forward P/E Ratio N/A
EPS -1.00
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 63
Country USA
Website PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
*Chart delayed
Analyzing fundamentals for PMVP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PMVP Fundamentals page.

Watching at PMVP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PMVP Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙